A retrospective study compared posttransplant engraftment parameters in 203 patients with myelofibrosis (MF) with those in a population of 203 matched controls without MF. There were no significant differences between these groups in the proportions of patients who died without achieving engraftment and in the disease-free survival distributions. Furthermore, comparisons between the two groups of patients reaching the respective endpoints showed no differences in the time distributions for reaching 0.5 or 1.0 x lo9/ L granulocytes, but the time to platelet transfusion independence was 3 days longer in patients with MF. In further analysis, results for 33 patients with severe MF were compared with those of their respective controls. The proportions of patients with severe MF who died without reaching YELOFIBROSIS (MF) associated with hematologic malignancies can be reversed after marrow transplantati~n"~ but has been associated with delayed hematopoietic reconstitution.6 Delayed recovery with MF could result from a decrease in the number of microenvironment niches or space for the development of donor hematopoietic stem cells.' Other factors also might affect hematopoietic recovery after marrow transplantation. Allogeneic engraftment is influenced by factors such as transfusion history, HLA disparity, posttransplant treatment with methotrexate, and the number of stem cells and lymphoid cells.' In autologous transplantation, a diagnosis of acute myelogenous leukemia, a low number of progenitors infused, and a low marrow cell dose have been correlated with delayed hematopoietic recovery.'"" Persistence or reappearance of MF after bone marrow transplantation has been associated with relapse and graft failure, but the relationship between MF, engraftment, and survival has not been completely defined: We have examined results of marrow transplantation in patients with MF to reassess the validity of concerns raised in a previous study.6
L granulocytes, but the time to platelet transfusion independence was 3 days longer in patients with MF. In further analysis, results for 33 patients with severe MF were compared with those of their respective controls. The proportions of patients with severe MF who died without reaching YELOFIBROSIS (MF) associated with hematologic malignancies can be reversed after marrow transplantati~n"~ but has been associated with delayed hematopoietic reconstitution.6 Delayed recovery with MF could result from a decrease in the number of microenvironment niches or space for the development of donor hematopoietic stem cells.' Other factors also might affect hematopoietic recovery after marrow transplantation. Allogeneic engraftment is influenced by factors such as transfusion history, HLA disparity, posttransplant treatment with methotrexate, and the number of stem cells and lymphoid cells.' In autologous transplantation, a diagnosis of acute myelogenous leukemia, a low number of progenitors infused, and a low marrow cell dose have been correlated with delayed hematopoietic recovery.'"" Persistence or reappearance of MF after bone marrow transplantation has been associated with relapse and graft failure, but the relationship between MF, engraftment, and survival has not been completely defined : We have examined results of marrow transplantation in patients with MF to reassess the validity of concerns raised in a previous study.6
M MATERIALS AND METHODS
The records of patients receiving transplants at The Fred Hutchinson Cancer Research Center between December 1984 and December 1989 were examined, and 203 patients were identified as having MF. All patients had interpretable pretransplant bone marrow biopsies that were reviewed by two of the investigators on two occasions. In each biopsy, reticulin, collagen, or both was identified by special histologic stains. The amount of fibrosis was graded as moderate (grade 1 or 2) or severe (grade 3 or 4) according to the criteria of Dekmezian et al, which are based on the percentage of the marrow space involved by myelofibrosis." A population of 203 patients without myelofibrosis was selected on the basis of matching date of transplantation ( 2 1 year), diagnosis (acute lymphoblastic leukemia, chronic myelogenous leukemia, acute nonlymphocytic leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma), type of transplant (HLA-matched sibling, HLA-haploidentical or unrelated, or autologous), and age ( k 5 years). These characteristics are listed in Tables 1 and 2 . Autologous marrow for patients with lymphoid malignancies was treated with monoclonal antibodies and complement." Autologous marrow for patients with acute myeloid leukemia was treated with 4-hydroperoxycyclophosphamide whenever 2 4 X 10' total nucleated cellskg could be collected.*-'" Blood, Vol 86, No 12 (December 15), 1995: pp 4667-4673 these engraftment endpoints and the disease-free survival distributions in the two groups were similar. Among patients who reached the respective engraftment endpoints, there was no statistically significant difference in the pace of granulocyte recovery. In patients with severe MF, there was a 7-day delay in the time to reach platelet transfusion independence and a 2-day delay in the time to reach red blood cell independence, but the differences were not statistically significant. The present results do not substantiate concerns raised by earlier studies. MF may delay the time to reach platelet independence by approximately 3 days and may increase platelet transfusion requirements, but no other perturbation of hematopoietic reconstitution was apparent. 0 1995 by The American Society of Hematology.
Statistical analysis. Myeloid engraftment endpoints were the first of 3 consecutive days with granulocyte counts of at least 0.5 or 1.0 x IO9&. Platelet independence was defined as the first of 7 consecutive days with platelet counts of 20 X IO9& without platelet transfusions. The endpoint for red blood cell (RBC) independence was the first day of a 3-week interval without RBC transfusions. Engraftment failure was defined as death or relapse without having reached the respective engraftment endpoints. Survival was analyzed using Kaplan-Meier methods13 and the log-rank statistic.I4 Distributions for reaching engraftment endpoints and numbers of transfusions were compared with the Wilcoxon two-sample rank sum test. Comparisons of proportions were tested with the x ' statistic. Spearman's rank correlation coefficient was used to evaluate possible relationships between marrow cell dose and time to platelet independence.
RESULTS
The selection criteria for patients in this study assured that patients with MF and the controls had comparable age, diagnoses, type of transplantation, and date of transplantation ( Table 1) . Forty-four patients (21 %) with MF had HLAmismatched donors compared with 50 (25%) of the controls. The two groups had comparable gender distributions, conditioning regimens, and treatment with hematopoietic growth factors or methotrexate ( Table 2 ). The marrow cell dose was significantly lower for patients with MF than for controls ( P = .006, Wilcoxon rank sum test). The cumulative incidence of death or relapse without reaching a granulocyte count of 0.5 X 10y/L or 1.0 X lo9/ L or without reaching platelet transfusion independence was virtually identical in patients with MF and in controls ( Fig  I) . One of 12 MF patients enrolled in growth factor protocols and 2 of 10 controls who received granulocyte-macrophage colony-stimulating factor (GM-CSF) died before the absolute neutrophil count (ANC) surpassed 0.5 X 10y/L. For the entire population of patients and controls, the blood granulo- For personal use only. on January 22, 2018. by guest www.bloodjournal.org From cyte count reached 0.5 X 109/L at a median of 22 days after transplantation. Of the 19 patients who died after day 22 without reaching a granulocyte count of 0.5 X lo9& 10 had MF and 9 did not. Causes of death for these 19 patients are summarized in Table 3 . Graft failure was considered to be the major contributing cause of death in 4 of the 10 patients with MF and in 3 of the 9 control patients. One additional patient with grade 1 to 2 MF underwent a second transplantation after relapse and was later reinfused with donor marrow because of poor engraftment. Two additional control patients received booster infusions of marrow for graft failure and rejection and subsequently died after engraftment.
There were no differences between the allogeneic MF patients and their controls in the time distributions for reaching a granulocyte count of 0.5 or 1.0 X 109L (Fig 2A and B) , but there was a 3-day delay in the mean time to platelet transfusion independence for the group with MF (P = .14; Fig 2C) . Likewise, there were no differences in the pace of myeloid engraftment between the autologous MF patients and their controls (Fig 2D and E) , but platelet recovery was delayed in the MF group (P = .13; Fig 2F) . For the entire group of patients, a correlation was found between marrow cell dose and time to platelet independence (Spearman's rank correlation coefficient = -.1483, P = .009). However, in testing the two groups separately, a statistically significant correlation between cell dose and time to platelet independence was found for controls (Spearman's rank correlation coefficient = -.1782, P = .028) but not for MF patients (Spearman's rank correlation coefficient = -.0922, P = .252).
Engraftment parameters were compared for the 33 patients with grades 3 to 4 MF and their respective controls. Many of these patients had increased numbers of reticulocytes, nucleated RBCs, and immature myeloid cells together with tear drop erythrocytes, suggesting myelophthisic effects, but only 7 had a pretransplant ANC less than 1.0 X 1 0 9 L Four of these seven patients had myelodysplastic syndromes, 1 had acute erythroblastic leukemia, and the remaining 2 had received high-dose chemotherapy less than 1 month before referral for marrow transplantation. Twenty-seven (82%) of the 33 patients with severe fibrosis had posttransplant immunosuppression with methotrexate compared with 26 (79%) of their respective controls. Two patients with severe MF received GM-CSF compared with none in the respective controls. Patients with severe MF received an average of 2.7 X 10' marrow celldkg (range, 0.53 to 7.0 X 10' marrow cells/ kg) compared with 3.2 X 10' marrow cellskg (range, 1.1 to 7.4 X 10' marrow cells/kg) in the respective controls.
One patient with severe MF and 2 control patients died after day 22 without reaching a granulocyte count of 0.5 X 109/L ( Table 3) . One of the seven patients with severe neutropenia before transplantation died on day 16 after transplantation. The other 6 reached a neutrophil count of 0.5 X 109/L at an average of 20.5 days (range, 12 to 28 days), similar to the time for controls and other patients with MF. The time to reach 0.5 or 1.0 X 109/L granulocytes after transplantation was similar in patients with severe MF and in their respective controls (Fig 3) . There was a 7-day delay in the time to platelet transfusion independence in the group with severe MF (median, 30 v 23 days), although the difference was not statistically significant (Fig 3C) severe myelofibrosis and 37 days (range, 8 to 83 days) in DISCUSSION controls (Fig 4) . The number of RBC transfusions after Results of this study do not confirm h e findings of a transplantation was also similar in the two groups, but the previous study that indicated an adverse effect of severe MF number of platelet transfusions was larger in patients with on hematologic recovery after allogeneic marrow transsevere MF (P = .03; Table 4 ). curred only among patients with MF, time intervals from transplant to granulocyte engraftment and platelet and RBC transfusion independence were longer for patients with severe fibrosis than for controls, and patients with severe fibrosis required substantially more RBC and platelet transfusion support than controls. In that study, controls were selected by matching for age, gender, HLA disparity, and marrow cell dose, although the control group actually contained a disproportionately low number of patients with HLA-incompatible donors. Thirteen (87%) of the 15 patients with severe fibrosis had posttransplant immunosuppression with methotrexate compared with 17 (61%) of the 28 controls.
plantation. In that study, deaths without engraftment oc-
In the present study, we found no evidence that mild or even severe fibrosis had any effect on the interval from transplant to granulocyte engraftment or RBC transfusion SOLL ET AL independence. The interval from transplantation to platelet transfusion independence was prolonged by approximately 7 days in patients with severe fibrosis compared with controls. Patients with severe fibrosis also required more platelet transfusion support than controls, although there was no significant difference between the number of RBC transfusions between groups. Matching criteria for the selection of controls differed from those used for the previous study in that year of transplant and patient diagnosis were considered in the present study, whereas marrow cell dose and patient gender were not. In the present study, it is not possible to determine whether differences in platelet reconstitution were caused entirely by MF itself or by the lower marrow cell dose in patients with MF.
There are several possible explanations for the differences between the two studies. The most striking finding is the complete absence of primary or secondary graft failures among the controls in the previous study. To some extent, this fortuitous result might reflect an underrepresentation of patients with HLA disparity. Second, the proportions of patients treated with methotrexate were more closely balanced in the present study than in the previous study. Finally, the lack of delayed engraftment among patients with MF in the present study could reflect better supportive care, i mproved patient selection, or possibly less stringent criteria for diagnosis of M F at the microscopic level.
Studies of engraftment after marrow transplantation are often hampered by deaths before engraftment. In cases in which death occurred early after transplantation, graft failure may not have been a contributing factor. In cases in which death occurred later, graft failure could have been an important influence, but this remains difficult to assess because of the wide time range during which engraftment can occur. In the previous study, the analysis of the time interval from transplantation to engraftment or transfusion independence did not exclude patients who died before reaching the respective endpoints. Differences between groups were widened by the occurrence of graft failure among patients with severe fibrosis and not among controls.
In the present study, deaths without engraftment occurred both in patients with MF and in controls, and some of the For personal use only. on January 22, 2018. by guest www.bloodjournal.org From deaths without engraftment were clearly caused by graft failure. Because a Kaplan-Meier analysis relies on the assumption that deaths without engraftment are not caused by graft failure, we have not used this method in our analysis. Instead, we have separately analyzed the time distributions of deaths in patients who did not reach specified indicators of engraftment and the time distributions for reaching the same indicators among patients who did engraft. The separate presentation of these two endpoints enables a clear and unambiguous interpretation of engraftment in all patients regardless of whether engraftment actually occurred or not. Moreover, this method does not rely on any minimum survival time after transplantation in evaluating whether death could have been caused by lack of engraftment.
In most cases, MF involved less than 50% of the marrow space (grades 1 and 2), and only a minority of cases showed more than 50% replacement of the marrow space by reticulin or collagen (grades 3 and 4) . Neutropenia was not a characteristic pretransplant feature in patients with severe MF except in patients with myelodysplastic syndromes. In these patients, the neutropenia most likely resulted from a stem cell defect. Because neutropenia does not commonly occur in severe MF, even in cases with myelophthisic changes, there is no a priori reason to believe that MF would necessarily impair myeloid engraftment after marrow transplantation. Results in the present study confirm this expectation by showing that MF as a single variable is not a risk factor for graft failure or for delayed myeloid engraftment after allogeneic or autologous marrow transplantation.
